


PRODUCT INFORMATION



Obatoclox (mesylate)

Item No. 11499

CAS Registry No.: 803712-79-0
Formal Name: 2-[2-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-3-methoxy-2H-pyrrol-5-yl]-1H-indole, monomethanesulfonate
Synonym: GX15-070
MF: C₂₀H₁₉N₃O • CH₃SO₃H
FW: 413.5
Purity: ≥98%
UV/Vis.: λ_{max}: 287, 314, 352, 546 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Obatoclox (mesylate) is supplied as a crystalline solid. A stock solution may be made by dissolving the obatoclox (mesylate) in the solvent of choice, which should be purged with an inert gas. Obatoclox (mesylate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of obatoclox (mesylate) in these solvents is approximately 2, 11, and 5 mg/ml, respectively.

Description

Obatoclox is an antagonist of Bcl-2 family members containing four Bcl-2 homology domains, including Bcl-2, Bcl-W, Bcl-xL, and Mcl-1 (K_d = ~500 nM).¹ It prevents the interaction of these pro-survival proteins with Bax or Bak, thereby inducing apoptosis with up-regulation of Bim, release of cytochrome c, and activation of caspase-3.²⁻³ Obatoclox also induces autophagy in mouse embryo fibroblasts and in HeLa cells.⁴ This compound inhibits the growth of cancer cell lines and primary cancer isolates.²⁻³

References

1. Shore, G.C. and Viallet, J. Modulating the Bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. *Hematology Am. Soc. Hematol. Educ. Program* 226-230 (2005).
2. Konopleva, M., Watt, J., Contractor, R., et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclox). *Cancer Res.* **68(9)**, 3413-3420 (2008).
3. Trudel, S., Li, Z.H., Rauw, J., et al. Preclinical studies of the pan-Bcl inhibitor obatoclox (GX015-070) in multiple myeloma. *Blood* **109(12)**, 5430-5438 (2007).
4. Andreu-Fernández, V., Genovés, A., Messegue, A., et al. BH3-mimetics- and cisplatin-induced cell death proceeds through different pathways depending on the availability of death-related cellular components. *PLoS One* **8(2)**, e56881 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM